In the second part of his series on Siteserv, Tom Lyons reveals how two senior Siteserv figures sought to secure lucrative share deals from the sale and reports how the IBRC Commission uncovered a “pattern of secret negotiations”.
The IBRC Commission has almost concluded its mammoth probe into the sale of Siteserv to Denis O’Brien and circulated its second draft report to witnesses. Today, we publish the first of a three-part series by Tom Lyons into the deal.
The 30-year-old investment partnership between developer Brendan Hickey and Davy stockbrokers is coming to an end. New information has emerged about the properties put up for sale.
With a new US headquarters and a cross-Atlantic move on the horizon, Nuritas CEO and founder Dr Nora Khaldi discusses what led to the relocation and her plans for the next chapter of the company.
An analysis of the performance of Metropolitan Films, one of the country’s most commercially successful television and film productions companies, confirms that the industry is both highly cyclical and highly dependent on tax credits.
2020 was a mixed bag for the US vulture fund, with collections and valuations slowing down at some of the SPVs used to buy distressed loans here. Initial figures for 2021 show a clear bounce.
Described by Revenue as a “blatant misuse or abuse” of the tax code, a leveraged bond scheme gave rise to an inflated CGT loss of €34.6m for a husband and wife. But just how did it work? And why is the Revenue struggling to stop it?
Three years ago, the government moved to close off tax loopholes being used by institutional investors using Irish Real Estate Funds. New data reveals if the clampdown worked, and gives an insight into how they allocate their money.
Having raised €5m to date, the Dublin-based environmental data analytics start-up is about to add flood defence monitoring to its existing products monitoring the presence of contaminants in a range of situations. Its founder Stephen McNulty is on this week’s podcast.
Having last year closed a $45m series B, Irish biotech company Nuritas has revealed it is building its new North American headquarters in Connecticut. CEO Dr Nora Khaldi is also moving to the US to lead the strategic expansion.
© 2025 Currency Media Limited
